There are five steps in the drug development process, which are designed to help ensure that potential new therapies are both safe and effective. The Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP), which NORD and the Critical Path Institute (C-Path) are developing, will aid in these steps and help contribute to faster development of medications for rare diseases, 90% of which are still without an FDA-approved treatment. Together, NORD and C-Path have created a three-part video series, “Accelerating Rare Disease Drug Development." This is the first video in the series, addressing the basics of the drug development process.

Learn more: rarediseases.org/rdca-dap/